Omeros Corporation
$ 10.18
-0.20%
11 Jun - close price
- Market Cap 748,361,000 USD
- Current Price $ 10.18
- High / Low $ 10.48 / 10.02
- Stock P/E 9.07
- Book Value -0.88
- EPS 1.14
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.25 %
- ROE -5.76 %
- 52 Week High 17.65
- 52 Week Low 2.95
About
Omeros Corporation, a commercial-stage biopharmaceutical company, discovers, develops, and markets protein and small molecule therapies, and orphan indications targeting inflammation, complement-mediated diseases, central nervous system (CNS) disorders, and system-related diseases. immunological. The company is headquartered in Seattle, Washington.
Analyst Target Price
$40.00
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-05-13 | 2026-03-31 | 2025-11-13 | 2025-08-14 | 2025-05-15 | 2025-03-31 | 2024-11-13 | 2024-08-07 | 2024-04-01 | 2024-03-26 | 2023-11-09 | 2023-08-09 |
| Reported EPS | 0.9771 | -0.5464 | -0.34 | -0.43 | -0.5408 | -0.55 | -0.64 | -0.97 | -0.63 | -0.15 | -0.6 | -0.59 |
| Estimated EPS | -0.1244 | -0.5202 | -0.45 | -0.46 | -0.58 | -0.71 | -0.7 | -1.14 | -0.58 | -0.55 | -0.62 | -0.57 |
| Surprise | 1.1015 | -0.0262 | 0.11 | 0.03 | 0.0392 | 0.16 | 0.06 | 0.17 | -0.05 | 0.4 | 0.02 | -0.02 |
| Surprise Percentage | 885.4502% | -5.0365% | 24.4444% | 6.5217% | 6.7586% | 22.5352% | 8.5714% | 14.9123% | -8.6207% | 72.7273% | 3.2258% | -3.5088% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: OMER
2026-06-10 19:40:19
H.C. Wainwright has reiterated a Buy rating and a $40.00 price target for Omeros Corp. despite the stock's recent weakness and an apparent overvaluation by InvestingPro analysis. The firm believes the market is under-appreciating Omeros's lead product, YARTEMLEA, especially given its strong early U.S. launch and differentiated mechanism. Upcoming data releases from EHA 2026 and ISTH 2026 are anticipated to further support YARTEMLEA's position in the market.
2026-06-10 12:09:33
H.C. Wainwright has reiterated its Buy rating and $40 price target for Omeros Corp. (NASDAQ:OMER), despite the stock experiencing a significant year-to-date decline. The firm believes the market is under-discounting the potential of positive ravulizumab data and highlighted YARTEMLEA's strong early U.S. launch and differentiated mechanism. Omeros recently reported a Q1 2026 earnings and revenue miss, but the company remains optimistic about YARTEMLEA's commercialization and its cash position.
2026-06-02 07:39:55
Omeros Corporation is initiated with a Hold rating due to the balanced risk/reward profile following YARTEMLEA's encouraging commercial launch. While Q1 2026 sales exceeded expectations, long-term adoption and payer confidence remain concerns due to limited clinical data. The valuation appears to price in specific peak sales figures, and upcoming catalysts include J-code, NTAP, EMA decision, and ex-US partnerships.
2026-06-01 16:10:37
Omeros Corporation reported significant events in Q4 2025, including a $2.1 billion asset transaction with Novo Nordisk for zaltenibart and FDA approval for YARTEMLEA, marking the first and only approved treatment for TA-TMA. The company also announced strong initial commercial launch progress for YARTEMLEA, with rapid P&T committee approvals and high payer reimbursement rates. Financially, Omeros achieved a net income of $86.5 million, repaid substantial debt, and expects YARTEMLEA to be self-sustaining in 2026, leading to positive company cash flow by 2027.
2026-06-01 15:38:57
Omeros (OMER) announced pivotal fourth-quarter 2025 results, highlighted by the divestiture of zaltenibart rights to Novo Nordisk for up to $2.1 billion and the FDA approval and U.S. launch of YARTEMLEA for TA-TMA. The company reported a net income of $86.5 million and significantly strengthened its balance sheet by repaying substantial debt. Omeros also detailed successful early adoption and reimbursement for YARTEMLEA and provided updates on its diverse clinical pipeline.
2026-05-28 02:39:32
Omeros Corp director Thomas J. Cable sold 7,500 shares of company stock worth $87,039 on May 22, 2026, as part of a Rule 10b5-1 trading plan. This transaction followed his exercise of vested stock options for the same number of shares. The sale occurred after a significant stock gain over the past year, though the stock recently declined and is trading above its fair value according to InvestingPro analysis.
